The Role of Ras Oncogene Mutations in Acute Myeloid Leukemia Patients: A Meta-analysis Based on 2502 Cases

Abstract

Background: the ras oncogene mutations frequently occurred in acute myeloid leukemia (AML), but as a prognostic factor remains inconclusive. Methods: The databases of PubMed, Web of Science, EMBASE, and the Cochrane. 22 eligible studies were included this study and analysis was conducted by Comprehensive Meta-Analysis Version 2 software program. All eligible study’s quality assessment refers to the European Lung Cancer Party quality scale. Results: Combined analysis showed that ras oncogene mutation was a poor impact on survival in AML patients (Hazard ratios (HRs): 1.50, 1.19-1.89, p <0.001). Nras gene mutation was a worse survival marker in AML (HR: 1.97, 95% CI: 1.35-2.89, p <0.001) and Kras gene mutations was no significance (HR: 1.32, 95% CI: 0.83-2.09, p =0.24) by stratified analysis. In the analysis of age bracket, adults with ras gene mutation had an unfavorable survival (HR: 1.55, 95% CI: 1.19-2.21, p =0.01) and children harbored ras gene mutation was not significantly with prognosis (HR: 1.22, 95% CI: 0.97-1.53, p =0.09) in AML. Conclusions: This study indicated that AML patients was poor prognosis especially in adult group with ras oncogene mutation, in which Nras mutation, but not Kras mutation involved in guiding survival.